Pfizer taps CFO with turnaround experience

Share this article:
Frank D'Amelio, who held top financial and operations posts in the telecom industry, is Pfizer's pick for CFO.

He replaces former CFO Alan Levin, who resigned in May.

The new hire's credentials speak volumes about Pfizer's priorities. CEO Jeffrey Kindler, just past the year mark as chief executive, is in the midst of orchestrating a turnaround for the company. Near the top of his list is finding a way to replace the $12 billion in annual revenue for Lipitor, Pfizer's top-seller which is set to lose US patent protection in 2011. Thus far the company has sought to do that through cost-cutting and seeking to beef up the pipeline.

D'Amelio will help address the challenges. In a statement today, the company hailed his 30 years of experience at AT&T, Lucent Technologies and Alcatel-Lucent, including serving as both COO and CFO at Lucent. During his tenure there, he helped steward Lucent's sale to French firm Alcatel.

“Frank was a senior executive in global companies undergoing the kind of rapid and complex changes we have undertaken at Pfizer in response to our own rapidly changing markets,” Kindler said in a statement.

Kindler also cited D'Amelio's experience working with the investment community. Kindler reached out to analysts early on in his tenure, in a marked departure from the more stoic approach of his predecessor, former Pfizer CEO Hank McKinnel.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...